RU2766354C2 - Вакцинные конструкты и их применения против инфекций стафилококка - Google Patents

Вакцинные конструкты и их применения против инфекций стафилококка Download PDF

Info

Publication number
RU2766354C2
RU2766354C2 RU2019115303A RU2019115303A RU2766354C2 RU 2766354 C2 RU2766354 C2 RU 2766354C2 RU 2019115303 A RU2019115303 A RU 2019115303A RU 2019115303 A RU2019115303 A RU 2019115303A RU 2766354 C2 RU2766354 C2 RU 2766354C2
Authority
RU
Russia
Prior art keywords
seq
polypeptide
lys
aureus
staphylococcus aureus
Prior art date
Application number
RU2019115303A
Other languages
English (en)
Russian (ru)
Other versions
RU2019115303A (ru
RU2019115303A3 (https=
Inventor
Франсуа МАЛУЕН
Селин СТЕР
Жюли КОТЕ-ГРАВЕЛЬ
Эрик БРУЙЕТТ
Original Assignee
Сокпра Сайенс Э Жени С.Е.К.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сокпра Сайенс Э Жени С.Е.К. filed Critical Сокпра Сайенс Э Жени С.Е.К.
Publication of RU2019115303A publication Critical patent/RU2019115303A/ru
Publication of RU2019115303A3 publication Critical patent/RU2019115303A3/ru
Application granted granted Critical
Publication of RU2766354C2 publication Critical patent/RU2766354C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2019115303A 2016-10-21 2017-10-20 Вакцинные конструкты и их применения против инфекций стафилококка RU2766354C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21
US62/411,120 2016-10-21
PCT/CA2017/051253 WO2018072031A1 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022100889A Division RU2022100889A (ru) 2016-10-21 2017-10-20 Вакцинные конструкты и их применения против инфекций стафилококка

Publications (3)

Publication Number Publication Date
RU2019115303A RU2019115303A (ru) 2020-11-23
RU2019115303A3 RU2019115303A3 (https=) 2021-03-02
RU2766354C2 true RU2766354C2 (ru) 2022-03-15

Family

ID=62018642

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019115303A RU2766354C2 (ru) 2016-10-21 2017-10-20 Вакцинные конструкты и их применения против инфекций стафилококка
RU2022100889A RU2022100889A (ru) 2016-10-21 2017-10-20 Вакцинные конструкты и их применения против инфекций стафилококка

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2022100889A RU2022100889A (ru) 2016-10-21 2017-10-20 Вакцинные конструкты и их применения против инфекций стафилококка

Country Status (24)

Country Link
US (2) US11324815B2 (https=)
EP (1) EP3529260A4 (https=)
JP (2) JP7181208B2 (https=)
KR (1) KR20190082229A (https=)
CN (1) CN109843910A (https=)
AR (1) AR109847A1 (https=)
AU (2) AU2017346974B2 (https=)
BR (1) BR112019007796A2 (https=)
CA (1) CA3037070A1 (https=)
CL (1) CL2019001048A1 (https=)
CO (1) CO2019005169A2 (https=)
CR (1) CR20190249A (https=)
DO (1) DOP2019000102A (https=)
IL (1) IL265869A (https=)
MX (2) MX2019004539A (https=)
MY (1) MY195369A (https=)
NZ (1) NZ751880A (https=)
PE (1) PE20191320A1 (https=)
PH (1) PH12019500843A1 (https=)
RU (2) RU2766354C2 (https=)
SG (2) SG10201912431XA (https=)
TW (1) TW201819402A (https=)
UY (1) UY37448A (https=)
WO (1) WO2018072031A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
WO2022125928A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2521501C2 (ru) * 2004-09-22 2014-06-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
RU2013154779A (ru) * 2009-04-14 2015-06-20 Новартис Аг Композиции для иммунизации против staphylococcus aureus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE50983T1 (de) 1985-01-07 1990-03-15 Syntex Inc Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
EP2298341A3 (en) * 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006059846A1 (en) 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
BRPI1011856A2 (pt) 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
LT2547361T (lt) 2010-03-17 2020-12-28 Socpra - Sciences Et Génie, S.E.C. Staphylococcus aureus bakterinės vakcinos komponentai ir jų naudojimas
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2521501C2 (ru) * 2004-09-22 2014-06-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
RU2013154779A (ru) * 2009-04-14 2015-06-20 Новартис Аг Композиции для иммунизации против staphylococcus aureus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369. *
MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 249, n. 2, p.147-152. *
SPENCER A. J. et al., Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates, PloS one, 2012, V. 7, N. 3, p.e33555. *
SPENCER A. J. et al., Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates, PloS one, 2012, V. 7, N. 3, p.e33555. CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369. MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 249, n. 2, p.147-152. *

Also Published As

Publication number Publication date
EP3529260A1 (en) 2019-08-28
RU2019115303A (ru) 2020-11-23
US20190216913A1 (en) 2019-07-18
WO2018072031A1 (en) 2018-04-26
CL2019001048A1 (es) 2019-08-30
RU2022100889A (ru) 2022-04-06
EP3529260A4 (en) 2020-12-16
KR20190082229A (ko) 2019-07-09
BR112019007796A2 (pt) 2019-09-03
MY195369A (en) 2023-01-16
SG10201912431XA (en) 2020-02-27
JP2019531100A (ja) 2019-10-31
NZ751880A (en) 2023-04-28
AR109847A1 (es) 2019-01-30
CA3037070A1 (en) 2018-04-26
IL265869A (en) 2019-06-30
MX2019004539A (es) 2019-06-12
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
AU2017346974B2 (en) 2022-03-31
UY37448A (es) 2018-03-23
JP2023025066A (ja) 2023-02-21
DOP2019000102A (es) 2019-07-15
PH12019500843A1 (en) 2019-12-02
JP7181208B2 (ja) 2022-11-30
US20220288183A1 (en) 2022-09-15
PE20191320A1 (es) 2019-09-24
US11324815B2 (en) 2022-05-10
MX2023001219A (es) 2023-03-03
CO2019005169A2 (es) 2019-08-09
CN109843910A (zh) 2019-06-04
SG11201901483QA (en) 2019-03-28
RU2019115303A3 (https=) 2021-03-02
AU2017346974A1 (en) 2019-03-14
CR20190249A (es) 2019-10-16

Similar Documents

Publication Publication Date Title
US11129884B2 (en) Bacterial vaccine components and uses thereof
Lin Novel approaches for Campylobacter control in poultry
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
Valderrama et al. Outer membrane protein FrpA, the siderophore piscibactin receptor of Photobacterium damselae subsp. piscicida, as a subunit vaccine against photobacteriosis in sole (Solea senegalensis)
US20230256071A1 (en) Virulent aeromonas vaccines and methods
Chen et al. Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia
US9597386B2 (en) Outer membrane proteins of Histophilus somni and methods thereof
HK40007546A (en) Vaccine constructs and uses thereof against staphylococcus infections
Schuijffel A strategic approach for immunity-based selection of cross-protective Ornithobacterium rhinotracheale antigens
Lowry Identification of novel gene products associated with virulence of Brucella abortus using gene discovery and targeted approaches